BGM
LXEO icon

Burkehill Global Management’s Lexeo Therapeutics LXEO Stock Holding History

Burkehill Global Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$582K Hold
125,000
– – 0.02% 164
2026
Q1 		$718K Hold
125,000
– – 0.04% 168
2025
Q4 		$1.24M Buy
+125,000
New +$1.14M 0.08% 141

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Burkehill Global Management's LXEO Position: Q2 2026 in Review

Burkehill Global Management held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 125,000 shares worth $582K. The position accounts for 0.02% of the portfolio, ranked #164.

Burkehill Global Management first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.24M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Burkehill Global Management held 125,000 shares of Lexeo Therapeutics worth $582K as of Q2 2026.
  • Burkehill Global Management left its Lexeo Therapeutics share count unchanged in Q2 2026.
  • Lexeo Therapeutics made up 0.02% of Burkehill Global Management's portfolio in Q2 2026, its #164 holding.
  • Burkehill Global Management first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Burkehill Global Management's Lexeo Therapeutics position peaked at $1.24M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.